The accompanying
notes are an integral part of these unaudited condensed financial statements (restated).
The accompanying
notes are an integral part of these unaudited condensed financial statements (restated).
The accompanying
notes are an integral part of these unaudited condensed financial statements (restated).
The accompanying
notes are an integral part of these unaudited condensed financial statements (restated).
NOTES TO
UNAUDITED CONDENSED FINANCIAL STATEMENTS
(Restated)
Note 1—Organization and Business Operations
Organization and General
Bannix Acquisition
Corp. (the “Company”) is a newly organized blank check company incorporated in the state of Delaware on January 21,
2021. The Company was formed for the purpose of effecting mergers, capital stock exchange, asset acquisitions, stock purchases,
reorganization or similar business combinations with one or more businesses (“Business Combination”). The Company has
not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, initiated any substantive
discussions, directly or indirectly, with any Business Combination target with respect to the Business Combination.
As of March
31, 2022, the Company had not commenced any operations. All activity for the period from January 21, 2021 (inception) through March
31, 2022 relates to the Company’s formation and the initial public offering (the “IPO”) (as defined below). The
Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest.
The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived
from the IPO. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks
associated with early stage and emerging growth companies.
Financing
The Company’s
sponsors are Subash Menon and Sudeesh Yezhuvath (through their investment entity Bannix Management LLP), Suresh Yezhuvath (“Yezhuvath”)
and Seema Rao (“Rao”) (the “Sponsors”).
The registration statements
for the Company’s IPO were declared effective on September 9, 2021 (the “Effective Date”). On September 14, 2021, the
Company consummated its IPO of 6,900,000 units at $10.00 per unit (the “Units”), which is discussed in Note 3. Each Unit consists
of one share of common stock (the “Public Shares”), one redeemable warrant to purchase one share of common stock at a price
of $11.50 per share and one right. Each right entitles the holder thereof to receive one-tenth (1/10) of one share of common stock upon
the consummation of the Business Combination.
Concurrent
with the IPO, the Company consummated the issuance of 406,000 private placement units (the “Private Placement Units”)
as follows: the Company sold 181,000 Private Placement Units to certain investors for aggregate cash proceeds of $2,460,000 and
issued an additional 225,000 private placement units to the Sponsor in exchange for the cancellation of $1,105,000 in loans and
a promissory note due to them (see Note 5). Each Private Placement Unit consists of one share of common stock, one redeemable
warrant to purchase one share of common stock at a price of $11.50 per whole share and one right. Each right entitles the holder
thereof to receive one-tenth (1/10) of one share of common stock upon the consummation of the Business Combination. The Company’s
management has broad discretion with respect to the specific application of the net proceeds of the IPO and the Private Placement
Units, although substantially all of the net proceeds are intended to be generally applied toward consummating a Business Combination.
Transaction
costs incurred related to the IPO were $8,746,087, consisting of $1,845,000 in underwriter’s discount paid at the time of
the offering, $225,000 in underwriting expense to be paid in the future, $2,861,040 in fair value of representative shares to the
underwriters, $3,244,453 in fair value of Anchor Investors shares, $10,834 fair value of Associate shares and $559,760 in other
offering costs. Of the total incurred, $33,223 was allocated to the warrants and charged to expense and $8,712,864 was charged
to temporary equity.
Trust Account
Following the closing of the IPO on
September 14, 2021, an amount of $69,690,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the IPO and Private
Placement Units was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within
the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 180 days or less or in any open-ended
investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act,
as determined by the Company. Except with respect to interest earned on the funds held in the Trust Account that may be released
to the Company to pay its franchise and income tax obligations (less up to $100,000 of interest to pay dissolution expenses), the
proceeds from this offering and the sale of the Private Placement Units will not be released from the Trust Account until the earliest
of (a) the completion of the Company’s initial Business Combination, (b) the redemption of any Public Shares properly submitted
in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation, and (c) the
redemption of the Company’s Public Shares if the Company is unable to complete the initial Business Combination within 15
months from the closing of this offering, or within any period of extension, subject to applicable law. The proceeds deposited
in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over
the claims of the Company’s public stockholders.
Initial Business Combination
The Company has 15 months from
the closing of the offering to consummate the initial Business Combination. However, if the Company anticipates that it may not
be able to consummate the initial Business Combination within 15 months, the Company may, by resolution of the board if requested
by the initial stockholders, extend the period of time to consummate a Business Combination up to two times, each by an additional
three months (for a total of up to 21 months to complete a Business Combination) (the “Combination Period”), subject
to the Sponsors depositing additional funds into the Trust Account as set out below. Pursuant to the terms of the bylaws and the
trust agreement entered into between the Company and Continental Stock Transfer & Trust Company on the date of this prospectus,
in order to extend the time available for the Company to consummate the initial Business Combination, the Sponsors, upon five days
advance notice prior to the applicable deadline, must deposit into the Trust Account for each three-month extension, $690,000
($0.10 per share in either case) on or prior to the date of the applicable deadline, up to an aggregate of $1,380,000, or approximately
$0.20 per share. In the event that the Company receives notice from the Sponsors five days prior to the applicable deadline of
its wish for the Company to effect an extension, the Company intends to issue a press release announcing such intention at least
three days prior to the applicable deadline. In addition, the Company intends to issue a press release the day after the applicable
deadline announcing whether or not the funds had been timely deposited. The Sponsors and its affiliates or designees are not obligated
to fund the Trust Account to extend the time for the Company to complete the initial Business Combination. If the Company is unable
to consummate the initial Business Combination within the applicable time period, the Company will, promptly but not more than
ten business days thereafter, redeem the Public Shares for a pro rata portion of the funds held in the Trust Account and promptly
following such redemption, subject to the approval of the remaining stockholders and the board of directors, dissolve and liquidate,
subject in each case to the obligations under Delaware law to provide for claims of creditors and the requirements of other applicable
law. In such event, the rights and warrants will be worthless. Additionally, pursuant to Nasdaq rules, any initial Business Combination
must be approved by a majority of the independent directors.
The Company anticipates structuring
the initial Business Combination so that the post-transaction company in which the public stockholders own shares will own
or acquire substantially all of the equity interests or assets of the target business or businesses. The Company may, however,
structure the initial Business Combination such that the post-transaction company owns or acquires less than substantially
all of such interests or assets of the target business in order to meet certain objectives of the target management team or stockholders
or for other reasons, but the Company will only complete such Business Combination if the post-transaction company owns or
acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target
sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended
(the “Investment Company Act”). Even if the post-transaction company owns or acquires 50% or more of the voting
securities of the target, the stockholders prior to the initial Business Combination may collectively own a minority interest in
the post-transaction company, depending on valuations ascribed to the target and the Company in the Business Combination transaction.
For example, the Company could pursue a transaction in which the Company issue a substantial number of new shares in exchange for
all of the outstanding capital stock of shares or other equity interests. In this case, the Company would acquire a 100% controlling
interest in the target. However, as a result of the issuance of a substantial number of new shares, the stockholders immediately
prior to the initial Business Combination could own less than a majority of the outstanding shares subsequent to the initial Business
Combination. If less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the
post-transaction company, the portion of such business or businesses that is owned or acquired is what will be valued for
purposes of the 80% of net assets test. If the initial Business Combination involves more than one target business, the 80% of
net assets test will be based on the aggregate value of all of the target businesses even if the acquisitions of the target businesses
are not closed simultaneously.
Although the Company believes that the
net proceeds of the offering will be sufficient to allow the Company to consummate a Business Combination, because the Company
has not yet identified any prospective target business, the Company cannot ascertain the capital requirements for any particular
transaction. If the net proceeds of this offering prove to be insufficient, either because of the size of the Business Combination,
the depletion of the available net proceeds in search of a target business, or because the Company becomes obligated to redeem
a significant number of the Public Shares upon consummation of the initial Business Combination, the Company will be required to
seek additional financing, in which case the Company may issue additional securities or incur debt in connection with such Business
Combination. Furthermore, the Company may issue a substantial number of additional shares of common or preferred stock to complete
the initial Business Combination or under an employee incentive plan upon or after consummation of the initial Business Combination.
The Company does not have a maximum debt leverage ratio or a policy with respect to how much debt the Company may incur. The amount
of debt the Company will be willing to incur will depend on the facts and circumstances of the proposed Business Combination and
market conditions at the time of the potential Business Combination. At this time, the Company is not party to any arrangement
or understanding with any third party with respect to raising additional funds through the sale of the securities or the incurrence
of debt. Subject to compliance with applicable securities laws, the Company would only consummate such financing simultaneously
with the consummation of the initial Business Combination.
Nasdaq rules require that the initial
Business Combination must occur with one or more target businesses that together have an aggregate fair market value of at least
80% of the assets held in the Trust Account (excluding advisory fees and taxes payable on the income earned on the Trust Account)
at the time of the agreement to enter into the initial Business Combination. If the board is not able to independently determine
the fair market value of the target business or businesses, the Company will obtain an opinion from an independent investment banking
firm or an independent accounting firm with respect to the satisfaction of such criteria. The Company does not intend to purchase
multiple businesses in unrelated industries in connection with the initial Business Combination.
The Company will provide its public
stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of the initial Business
Combination either (i) in connection with a stockholder meeting called to approve the initial Business Combination or (ii) by
means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial Business Combination
or conduct a tender offer will be made by the Company, solely at its discretion. The stockholders will be entitled to redeem their
shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.10 per share, plus
any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations).
The initial carrying value of the common
stock subject to redemption is recorded at an amount equal to the proceeds of the public offering less (i) the fair value of the
public warrants and less (ii) offering costs allocable to the common stock sold as part of the units in the IPO. Such initial carrying
value is classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”)
Topic 480 “Distinguishing Liabilities from Equity.”
The Company’s amended and restated
certificate of incorporation provides that in no event will it redeem the public shares in an amount that would cause the Company’s
net tangible assets to be less than $5,000,001 both immediately before and after the consummation of the Business Combination (so
that the Company is not subject to the SEC’s “penny stock” rules). Redemptions of the Company’s public
shares may also be subject to a higher net tangible asset test or cash requirement pursuant to an agreement relating to the Business
Combination. For example, the Business Combination may require: (i) cash consideration to be paid to the target or its owners,
(ii) cash to be transferred to the target for working capital or other general corporate purposes or (iii) the retention of cash
to satisfy other conditions in accordance with the terms of the Business Combination. In the event the aggregate cash consideration
the Company would be required to pay for all shares of common stock that are validly submitted for redemption plus any amount required
to satisfy cash conditions pursuant to the terms of the Business Combination exceed the aggregate amount of cash available to the
Company, it will not complete the Business Combination or redeem any shares, and all shares of common stock submitted for redemption
will be returned to the holders thereof.
The Sponsors, officers and directors
and Representative (as defined in Note 6) have agreed to (i) waive their redemption rights with respect to their Founder Shares
and Public Shares in connection with the completion of the initial Business Combination, (ii) waive their redemption rights
with respect to their Founder Shares (as defined below) and Public Shares in connection with a stockholder vote to approve an amendment
to the Company’s amended and restated certificate of incorporation, and (iii) waive their rights to liquidating distributions
from the Trust Account with respect to their Founder Shares if the Company fails to complete the initial Business Combination within
the Combination Period.
The Company’s Sponsors have agreed
that they will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold
to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality
or similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of
(i) $10.10 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation
of the Trust Account, if less than $10.10 per share due to reductions in the value of the trust assets, less taxes payable, provided
that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and
all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims
under the Company’s indemnity of the underwriters of this offering against certain liabilities, including liabilities under
the Securities Act. However, the Company has not asked its Sponsors to reserve for such indemnification obligations, nor has the
Company independently verified whether its Sponsors have sufficient funds to satisfy its indemnity obligations and believe that
the Company’s Sponsors’ only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsors
would be able to satisfy those obligations.
Liquidity,
Capital Resources and Going Concern
As of March 31, 2022, the Company had
$228,182 in cash and working capital of $178,333.
The Company’s liquidity needs
through March 31, 2022 were satisfied through (1) a capital contribution from the Sponsors of $28,750 for common stock (“Founder
Shares”) and (2) loans from Sponsors and related parties in order to pay offering costs. In addition, in order to fund transaction
costs in connection with a possible Business Combination, the Company’s Sponsors, an affiliate of the Sponsors, and/or certain
of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans. As of March
31, 2022, the Company owed $43,890 to Sponsors and related parties. See Note 5 for further disclosure of Sponsor and related party
loans.
Based on the foregoing, management believes
that the Company may not have sufficient funds and borrowing capacity to meet its operating needs through the consummation of a
Business Combination through the initial term of the Company which expires on December 14, 2022. Over this time period, the Company
will be utilizing these funds to pay existing accounts payable, identifying and evaluating prospective initial Business Combination
candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business
to merge with or acquire, and structuring, negotiating and consummating the Business Combination. As of the date of the filing
of this report, management has indicated that it does intend to extend the term of the Company after its initial term expires.
The Company is within 12 months of its mandatory liquidation
date as of the date of the filing of this report. In connection with the Company’s assessment of going concern considerations, the
Company has until December 14, 2022 to consummate a Business Combination. It is uncertain that the Company will be able to consummate
a Business Combination by that time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation
and subsequent dissolution of the Company. We have determined that the insufficient funds to meet the operating needs of the Company through
the liquidation date as well as the mandatory liquidation, should a business combination not occur, and potential subsequent dissolution
raises substantial doubt about our ability to continue as a going concern.
These financial statements do not include
any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary
should the Company be unable to continue as a going concern.
Risks
and Uncertainties
Management
is currently evaluating the impact of the COVID-19 pandemic on the Company and has concluded that while it is reasonably possible
that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search
for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.
In February
2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various
nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the
impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements.
The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable
as of the date of these financial statements.
Consideration of Inflation Reduction
Act Excise Tax
On August 16, 2022, the Inflation Reduction
Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal
1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries
of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation
itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market
value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing
corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases
during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the
“Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or
avoidance of the excise tax.
Any redemption or other repurchase that
occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise
tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension
vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in
connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature
and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not
in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content
of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not
by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could
cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete
a Business Combination.
Note 2– Restatement of Previously
Issued Financial Statements
In connection with the audit of the
Company’s financial statements for the period ended December 31, 2021, the Company’s management further evaluated the
warrants under Accounting Standards Codification (“ASC”) Subtopic 815-40, Contracts in Entity’s Own Equity. ASC
Section 815-40-15 addresses equity versus liability treatment and classification of equity-linked financial instruments, including
warrants and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed
to the issuer’s common stock. Based on management’s evaluation, the Company’s audit committee, in consultation
with management, concluded that the Company’s Public Warrants are indexed to the Company’s common stock. As a result,
the Company should have classified the Public Warrants as a component of equity in its previously issued financial statements.
Additionally, the Company evaluated
the impacts of the transfer of shares to Anchor Investors and other investors. The transfer of shares to the Anchor Investors and
other investors were valued as of the grant date and that value was allocated to the offering costs of the Company.
Associated with the reclassification
of the Public Warrants to equity and the valuation of the Anchor Investor shares, the allocation of offering costs was re-allocated.
The Company’s accounting for the
Public Warrants as derivative liabilities instead of as components of equity did not have any effect on the Company’s previously
reported investments held in trust, operating expenses, or cash.
The impact of the restatement on the
Company’s financial statements is reflected in the following tables:
Schedule of restatement
financial statements |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As
Reported |
|
Restatement |
|
As
Restated |
|
|
|
|
|
|
|
Balance
Sheet as of March 31, 2022 |
Warrant liability |
|
$ |
1,757,500 |
|
|
$ |
(1,656,000 |
) |
|
$ |
101,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities |
|
$ |
2,157,862 |
|
|
$ |
(1,656,000 |
) |
|
$ |
501,862 |
|
Common stock subject to possible redemption |
|
$ |
63,628,883 |
|
|
$ |
(2,517,797 |
) |
|
$ |
61,111,086 |
|
Additional paid-in capital |
|
$ |
892,069 |
|
|
$ |
7,883,643 |
|
|
$ |
8,775,712 |
|
Retained earnings (Accumulated deficit) |
|
$ |
3,342,899 |
|
|
$ |
(3,709,846 |
) |
|
$ |
(366,947 |
) |
Total Stockholders’ Equity |
|
$ |
4,260,208 |
|
|
$ |
4,173,797 |
|
|
$ |
8,434,005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Statement
of Operations for the three months ended March 31, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrant liabilities |
|
$ |
1,680,380 |
|
|
$ |
(1,587,000 |
) |
|
$ |
93,380 |
|
Total other income |
|
$ |
1,682,136 |
|
|
$ |
(1,587,000 |
) |
|
$ |
95,136 |
|
Net income (loss) |
|
$ |
1,497,256 |
|
|
$ |
(1,587,000 |
) |
|
$ |
(89,744 |
) |
Basic and diluted net income (loss) per share |
|
$ |
0.16 |
|
|
$ |
(0.17 |
) |
|
$ |
(0.01 |
) |
Statement of Changes in Stockholders' |
|
|
|
|
|
|
Equity for the three months ended March 31, 2022 |
|
As Reported |
|
Restatement |
|
As Restated |
|
|
|
|
|
|
|
Common stock subject to possible redemption, at
accreted value |
|
$
|
(2,164,684
|
)
|
|
$
|
(875,089
|
)
|
|
$
|
(3,039,773
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
1,497,256 |
|
|
$ |
(1,587,000 |
) |
|
$ |
(89,744 |
) |
Total Stockholders’ Equity |
|
$ |
4,260,208 |
|
|
$ |
4,173,797 |
|
|
$ |
8,434,005 |
|
|
|
As
Reported |
|
Restatement |
|
As
Restated |
Condensed Statement of Cash Flows for the three months ended March 31, 2022 |
|
|
Net income (loss) |
|
$ |
1,497,256 |
|
|
$ |
(1,587,000 |
) |
|
$ |
(89,744 |
) |
Change in fair value of warrant liabilities |
|
$ |
(1,680,380 |
) |
|
$ |
1,587,000 |
|
|
$ |
(93,380 |
) |
Supplemental disclosure of noncash financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Accretion of carrying value to redemption value |
|
$ |
2,164,684 |
|
|
$ |
875,089 |
|
|
$ |
3,039,773 |
|
Note 3—Significant
Accounting Policies
Basis
of Presentation
The accompanying financial statements
of the Company are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of
America for interim financial information (“US GAAP”) and pursuant to Rule 8-03 of Regulation S-X promulgated by the
U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes
required by US GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which
include only normal recurring adjustments necessary for the fair statement of the balances and results for the period presented.
Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected
through December 31, 2022.
Certain information and footnote disclosures normally
included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited
condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included
in the Company’s Annual Report on Form 10-K/A for the period January 21, 2021 (inception) through December 31, 2021 filed with the
SEC on November 3, 2022. The balance sheet as of December 31, 2021 contained herein has been derived from the audited financial statements
as of December 31, 2021, but does not include all disclosures required by U.S. GAAP.
Emerging
Growth Company Status
The Company
is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the
“Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and
it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic
reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt
out of such extended transition period which means that when a standard is issued or revised and it has different application dates
for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with
another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using
the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of these unaudited
condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited
condensed financial statements and the reported amounts of expenses during the reporting period.
Making estimates requires management
to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation
or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events.
Concentration
of Credit Risk
Financial instruments that potentially
subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, may exceed
the insured limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed
to significant risks on such accounts. As of March 31, 2022 and December 31, 2021, approximately $69,671,440 and $69,870,946 was
held in excess of insured limits, respectively.
Offering Costs related to the Initial Public Offering
The Company complies with
the requirements of ASC Subtopic 340-10-S99-1, “Expenses of Offering.” Offering costs consist of legal, accounting, underwriting
fees and other costs incurred through March 31, 2022 that were directly related to the IPO. Upon consummation of the IPO, offering costs
were allocated to the separable financial instruments issued in the IPO on a relative fair value basis compared to total proceeds received.
Offering costs associated with the Private Warrant liabilities were expensed as incurred and presented as non-operating expenses in the
statement of operations. Offering costs associated with the shares of common stock were charged to temporary equity (common stock subject
to possible redemption) upon the completion of the IPO. Offering costs associated with the Public Warrants were included in additional
paid-in capital on the statements of changes in stockholders’ equity.
Anchor
Investors and Other Investors
The Company
complies with SAB Topic 5.A to account for the valuation of the Founder Shares acquired by the Anchor Investors and Other Investors.
The Founder Shares acquired by the Anchor Investors and Other Investors represent a capital contribution for the benefit of the
Company and are recorded as offering costs and reflected as a reduction in the proceeds from the offering and offering expenses
in accordance with ASC 470 and Staff Accounting Bulletin Topic 5A. As such, upon sale of the Founder Shares to the Anchor Investors
and the granting of the Founder Shares to the Other Investors the valuation of these shares were recognized as a deferred offering
cost and charged to temporary equity and the statement of operations based on the relative fair value basis.
Fair Value of Financial Instruments
The fair value
of the Company’s cash and current liabilities approximates the carrying amounts represented in the accompanying balance sheet,
due to their short-term nature.
Fair value
is defined as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation
methodologies is as follows:
Level 1 Inputs
- Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access
at the measurement date.
Level 2 Inputs
- Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets
or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such
as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated
by market data by correlation or other means.
Level 3 Inputs
- Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about
the assumptions that market participants would use in pricing the assets or liabilities.
Fair Value
of Trust Account
As of March 31, 2022 and
December 31, 2021, the assets in the Trust Account were held in a money market fund with a broker. These financial assets were accounted
for at fair value on a recurring basis within Level 1 of the fair value hierarchy. The Company classifies its investments in the Trust
Account as available-for-sale in accordance with FASB ASC Topic 320 “Investments—Debt and Equity Securities.” Available-for-sale
securities are those securities not classified as trading securities or as held-to-maturity securities. Available-for-sale securities
are reported at fair value.
Fair Value
of Warrant Liability
The Company
accounted for the 7,306,000 warrants issued in connection with the IPO and private placement in accordance with the guidance contained
in ASC Topic 815, “Derivatives and Hedging” whereby under that provision, the Private Warrants did not meet the criteria
for equity treatment and were recorded as a liability and the Public Warrants met the criteria for equity treatment. Accordingly,
the Company classified the Private Warrants as a liability at fair value in the three months ended March 31, 2022 and adjusts them
to fair value at each reporting period. This liability is re-measured at each balance sheet date until the Private Warrants are
exercised or expire, and any change in fair value is recognized in the Company’s statements of operations.
Common Stock Subject to Redemption
The Company accounts for its common
stock subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.”
Common stock subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally
redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder
or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified
as temporary equity and subsequently measured at redemption value. At all other times, shares of common stock are classified as
stockholders’ equity. The Company’s shares of common stock sold as part of the IPO feature certain redemption rights
that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly,
all 6,900,000 shares of common stock subject to possible redemption are presented at their net carrying value and classified as
temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. The initial carrying
value of the common stock subject to redemption is recorded at an amount equal to the proceeds of the public offering ($69,000,000)
less (i) the fair value of the public warrants ($5,796,000) and less (ii) offering costs allocable to the common stock sold as
part of the units in the public offering ($8,712,864). In accordance with the alternative methods described in ASC Subtopic 480-10-S99-3A(15),
“Classification and Measurement of Redeemable Securities.” The Company has made an accounting policy election to accrete
changes in the difference between the initial carrying amount and the redemption amount ($10.10 per share) over the period form
the IPO date to the expected redemption date. For purposes of accretion, the Company has estimated that it will take 15 months
for a Business Combination to occur and accordingly will accrete the carrying amount to the redemption value using the effective
interest method over that period. Such changes are reflected in additional paid in capital, or in the absence of additional paid-in
capital, in accumulated deficit.
Net Loss Per Share
Basic net loss per share is computed
by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
For purposes of calculating diluted
income per common stock, the denominator includes both the weighted-average number of shares of common stock outstanding during
the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common
stock equivalents potentially include shares and warrants using the treasury stock method.
As of March 31, 2022, 7,306,000 warrants
were excluded from the diluted income per share calculation since the exercise price of the warrants is greater than the average
market price of the common stock. As a result, diluted net loss per share is the same as basic loss per share for the period presented.
Reconciliation of Loss per Share
of Common Stock
Basic and diluted loss per share for
common stock is calculated as follows:
Schedule of Reconciliation of Income per Share of Common Stock |
|
|
|
|
|
|
|
|
|
|
Three
months ended March 31, 2022 |
|
For
the period from January 21, 2021 (inception) to March 31, 2021 |
Loss
per share of common stock: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(89,744 |
) |
|
$ |
(1,033 |
) |
|
|
|
|
|
|
|
|
|
Weighted Average Shares of common stock |
|
|
9,424,000 |
|
|
|
2,875,000 |
|
Basic and diluted loss per share |
|
$ |
(0.01 |
) |
|
$ |
(0.00 |
) |
Income Taxes
Income taxes
are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future
tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be
realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the
period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets
to the amounts that are more likely than not to be realized from operations.
Tax benefits
of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position
taken on an income tax return. The Company has no liability for uncertain tax positions as of March 31, 2022 and December 31, 2021.
Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does
not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense
recognized during the three months ended March 31, 2022.
Recent
Accounting Pronouncements
In August 2020,
the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt
— “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s
Own Equity” (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06
eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments
and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own
equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed
to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement
to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied
on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU
2020-06 as of January 1, 2021 and the adoption of the ASU 2020-06 did not have a material effect on the financial statements.
Management
does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would
have a material effect on the Company’s financial statements.
Note 4— Initial
Public Offering
On September
14, 2021, the Company consummated its IPO and sold 6,900,000 Units at a purchase price of $10.00 per Unit, which was inclusive
of the underwriters’ full exercise of their over-allotment option, generating gross proceeds of $69,000,000. Each Unit that
the Company sold had a price of $10.00 and consisted of one share of common stock, one warrant to purchase one share of common
stock and one right. Each warrant will entitle the holder to purchase one share of common stock at a price of $11.50 per share,
subject to adjustment. Each warrant will become exercisable on the later of the completion of the initial Business Combination
or 12 months from the closing of the offering and will expire five years after the completion of the initial Business Combination,
or earlier upon redemption or liquidation. Each right entitles the holder to buy one tenth of one share of common stock. The common
stock, warrants and rights comprising the Units will begin separate trading on the 52nd day following September
13, 2021, the date of the filing of the final prospectus unless the underwriters, I-Bankers Securities, Inc., inform the Company
of their decision to allow earlier separate trading, subject to the Company’s having filed the Current Report on Form 8-K with
the accompanying audited balance sheet and having issued a press release announcing when such separate trading will begin. At the
time that the common stock, warrants and rights comprising the Units begin separate trading, holders will hold the separate securities
and no longer hold Units (without any action needing to be taken by the holders), and the Units will no longer trade.
All of the 6,900,000 shares of common
stock sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in
connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business
Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC
and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions
not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity.
The common stock is subject to SEC and
its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that
the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over
the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if
later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur
and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company
recognizes changes in redemption value over the period from the IPO date to the expected redemption date. The change in the carrying value of redeemable common stock resulted
in charges against additional paid-in capital and accumulated deficit.
As of March 31, 2022, the common stock
reflected on the balance sheet is reconciled in the following table:
Schedule of common stock reflected on
the balance sheet |
|
|
|
|
Common stock subject to possible redemption at December 31, 2021 |
|
$ |
58,071,313 |
|
Plus: |
|
|
|
|
Accretion of carrying value to redemption value |
|
|
3,039,773 |
|
Common stock subject to possible redemption at March 31, 2022 |
|
$ |
61,111,086 |
|
Note 5—Private
Placement
Simultaneously
with the closing of the IPO and the sale of the Units, the Company sold 181,000 Private Placement Units to certain investors for
aggregate cash proceeds of $2,460,000 and issued an additional 225,000 Private Placement Units to a Sponsor in exchange for the
cancellation of approximately $1,105,000 in loans and a promissory note due to them. Each Private Placement Unit consisted of one
share of common stock, one redeemable warrant to purchase one share of common stock at a price of $11.50 per whole share and one
right.
Note 6—Related Party Transactions
Founder
Shares
In February
2021, the Sponsors subscribed for 2,875,000 shares of the Company’s common stock (the “Founder Shares”) for $28,750,
or $0.01 per share, in connection with formation. In June 2021, 1,437,500 shares of the Founder Shares were re-purchased by the
Company for a total of $14,375. In connection with the upsize of the IPO, on June 10, 2021, an additional 287,500 Founder Shares
were issued via a 20% stock dividend, resulting in total Founder Shares outstanding of 1,725,000. All share amounts and related
figures were retroactively adjusted.
In
March 2021, Suresh Yezhuvath granted an aggregate of 16,668
Founder Shares to other investors (“Other
Investors”) at no costs.
The Sponsors,
Other Investors, Anchor Investors, directors and officer have agreed not to transfer, assign or sell the Founder Shares until the
earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) the date on which the Company
completes a liquidation, merger, stock exchange or other similar transaction after the initial Business Combination that results
in all of the public stockholders having the right to exchange their shares of common stock for cash, securities or other property.
The Company refers to such transfer restrictions as the “lock-up”. Notwithstanding the foregoing, if the last sale
price of the common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations
and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business
Combination, the Founder Shares will be released from the lock-up.
Working
Capital Loans – Sponsors
In order to
finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors or certain of
the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required. If the Company
completes a Business Combination, the Company would repay the loans out of the proceeds of the Trust Account released to the Company.
Otherwise, the loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination
does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the loans but no proceeds
from the Trust Account would be used to repay the loans.
Pre-IPO Promissory Note—Sponsor
On February
15, 2021, the Company issued an unsecured promissory note to Yezhuvath, as and when required, pursuant to which the Company may
borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of this offering. The note was
non-interest bearing and unsecured. As of March 31, 2022, all $300,000 of the note had been drawn down and fully repaid upon
the closing of the IPO through the issuance of 30,000 Private Placement Units.
Pre-IPO
Loans – Sponsors
Prior to the
completion of the IPO, the Company entered into an additional loan agreement with Yezhuvath to finance the expenses associated
with preparing for the IPO as follows:
The Company
entered into a loan agreement with Yezhuvath with the following terms:
|
1. |
The
Company borrowed approximately $805,000 under the loan agreement as follows: |
|
a. |
Deferred offering costs of $50,000 were directly paid by the Sponsor. |
|
b. |
The Company repurchased treasury stock of $7,375 from the Sponsor. |
|
c. |
Proceeds of approximately $747,625 was received directly into the Company from the Sponsor. |
|
2. |
Advances
under the loan agreement are unsecured and do not bear interest. |
|
3. |
Following
the consummation of the IPO, the loan was repaid/forfeited as follows: |
|
a. |
Against
the first approximate $1,030,000 of the note and loan agreement (inclusive of the $300,000 note discussed above), 205,000
Private Placement Units were issued. |
|
b. |
Against
the next $75,000 of loan, 20,000 Private Placement Units were issued. |
Yezhuvath agreed
to make an additional loan to the Company of $225,000 pursuant to the exercise of the over-allotment which would only be drawn
down at the time of the Business Combination. The proceeds would be used to pay a portion of the incremental underwriting discount
on the over-allotment shares which the underwriter has agreed to defer the receipt of until a Business Combination is consummated.
Yezhuvath has agreed to forgive this amount without any additional securities being issued against it.
On April 12,
2021, the Company entered into a loan agreement with Rao for an amount of $270,000. The loan did not bear interest and was unsecured.
In connection with the successful IPO, the loan was forfeited and not repaid by the Company and was considered a capital contribution
without any additional securities being issued.
Except as noted
above, the Company does not anticipate any future borrowings from Sponsors or affiliates as working capital loans. As of March
31, 2022 there are no outstanding balances payable to related parties under any working capital loan agreements.
Due to Related Parties
The balance
in Due to Related Parties totaling $43,890 consists of the following transactions:
1. |
Subash Menon paid expenses on behalf of the Company. As of March 31, 2022, the Company owed him $3,557 for such expenses. |
|
|
2. |
As a result of a change in the size of the offering, the Company agreed to repurchase 700,000 shares of common stock from Bannix Management LLP for total consideration of $7,000. |
|
|
3. |
Pursuant to the Administrative Support Agreement, the Company has accrued $33,333 for rent since September 2021 for which it was a publicly listed company.xxx |
Administrative
Support Agreement
Commencing
on the date of the IPO, the Company has agreed to pay an affiliate of the Sponsor for office space, secretarial and administrative
services provided to members of the management team, in the amount of $5,000 per month. Upon completion of the initial Business
Combination or the Company’s liquidation, it will cease paying these monthly fees. For the period ended March 31, 2022, the
Company had incurred $15,000 pursuant to the agreement. For the period from January 21, 2021 (inception) through March 31, 2021,
the Company did not incur any fees for these services.
Note 7—Commitments and Contingencies
Registration
Rights
The holders
of the Founder Shares, Private Placement Units and warrants that may be issued upon conversion of related party loans will have
registration rights to require the Company to register a sale of any of its securities held by them pursuant to a registration
rights agreement to be signed prior to or on the effective date of this offering. These holders will be entitled to make up to
three demands, excluding short form registration demands, that the Company registers such securities for sale under the Securities
Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration
statements filed by the Company.
Underwriters Agreement
The Company granted the underwriters
a 30-day option from the date of the IPO to purchase up to an additional 900,000 Units to cover over-allotments, which it fully
exercised on the date of the IPO.
The underwriters were entitled to a
cash underwriting discount of 3% of the gross proceeds of the IPO, or an aggregate of $2,070,000. Of this amount, $225,000 will
be payable to the underwriters by a Sponsor solely in the event that the Company completes a Business Combination, subject to the
terms of the underwriting agreement. Additionally, the underwriters are entitled to a Business Combination marketing fee of 3.5%
of the gross proceeds of the sale of Units in the IPO upon the completion of the Company’s initial Business Combination subject
to the terms of the underwriting agreement.
The Company issued the underwriter (and/or
its designees) (the “Representative”) 393,000 shares of common stock for $0.01 per share (the “Representative
Shares”) upon the consummation of the IPO. The Company accounted for the estimated fair value ($2,861,000) of the Representative
Shares as an offering cost of the IPO and allocated such cost against temporary equity for the amount allocated to the redeemable
shares and to expense for the allocable portion relating to the warrant liability. These shares of common stock issued to the underwriter
are subject to an agreement in which the underwriter has agreed (i) not to transfer, assign or sell any such shares until the completion
of the Business Combination. In addition, the underwriter (and/or its designees) has agreed (i) to waives its redemption rights
with respect to such shares in connection with the completion of the Business Combination and (ii) to waive its rights to liquidating
distributions from the trust account with respect to such shares if it fails to complete the Business Combination within 15 months
from the closing of the IPO. Accordingly, the fair value of such shares is included in stockholders’ equity. As of March
31, 2022, the Representative has not yet paid for these shares, and the amount owed of $3,930 is included in prepaid expenses on
the balance sheets.
Other
Investors
Other
Investors were granted an aggregate of 16,668 Founder Shares at no costs from Suresh Yezhuvath in March 2021. The Company valued
the Founder Shares at approximately $0.65 per share or $10,834 in the aggregate at the date of the grant.
The
Other Investors have not been granted any stockholder or other rights that are in addition to those granted to the Company’s
other public stockholders. The Other Investors will have no rights to the funds held in the Trust Account with respect to the Founder
Shares held by them. The Other Investors will have the same rights to the funds held in the Trust Account with respect to the common
stock underlying the Units they purchase at the IPO as the rights afforded to the Company’s other public stockholders.
The
Company complies with SAB Topic 5.A to account for the valuation of the Founder Shares acquired by the Other Investors. The Founder Shares
acquired by the Other Investors represent a capital contribution for the benefit of the Company and are recorded as offering costs and
reflected as a reduction in the proceeds from the offering and offering expenses in accordance with ASC 470 and Staff Accounting Bulletin
Topic 5A. As such, upon the granting of the Founder Shares to the Other Investors the valuation of these shares were recognized as a deferred
offering cost and charged to temporary equity and the statement of operations based on the relative fair value basis.
Anchor
Investors
The
Anchor Investors entered into separate letter agreements with the Company and the Sponsors pursuant to which, subject to the conditions
set forth therein, the Anchor Investors purchased, upon the closing of the IPO on September 14, 2021, 181,000 Private Placement
Units and 762,000 Founder Shares on September 9, 2021 (“Anchor Shares” in the total). The Company valued the Founder
Shares at $7.48 per share at the date of the purchase.
The
Anchor Investors have not been granted any stockholder or other rights that are in addition to those granted to the Company’s
other public stockholders and purchased the Founder Shares for nominal consideration with an excess of the fair value of $3,244,453.
Each Anchor Investor has agreed in its individually negotiated letter agreement entered into with the Company to vote its Anchor
Shares to approve the Company’s initial Business Combination. The Anchor Investors will have no rights to the funds held
in the Trust Account with respect to the Anchor Shares held by them. The Anchor Investors will have the same rights to the funds
held in the Trust Account with respect to the common stock underlying the Units they purchase at the IPO (excluding the common
stock included in the Private Placement Units purchased) as the rights afforded to the Company’s other public stockholders.
The
Company complies with SAB Topic 5.A to account for the valuation of the Founder Shares acquired by the Anchor Investors. The Founder Shares
acquired by the Anchor Investors represent a capital contribution for the benefit of the Company and are recorded as offering costs and
reflected as a reduction in the proceeds from the offering and offering expenses in accordance with ASC 470 and Staff Accounting Bulletin
Topic 5A. As such, upon sale of the Founder Shares to the Anchor Investors the valuation of these shares were recognized as a deferred
offering cost and charged to temporary equity and the statement of operations based on the relative fair value basis.
Note 8 — Warrant Liability
The Company accounted for the 7,306,000 warrants issued
in connection with the IPO and private placement in accordance with the guidance contained in ASC Topic 815 “Derivatives and Hedging”
whereby under that provision, the Private Warrants did not meet the criteria for equity treatment and were recorded as a liability. Accordingly,
the Company classified the Private Warrants as a liability at fair value and adjusts them to fair value at each reporting period. This
liability will be re-measured at each balance sheet date until the Private Warrants are exercised or expire, and any change in fair value
will be recognized in the Company’s statement of operations. The fair value of the Private Warrants was estimated using a modified
Black-Scholes model. The valuation models utilize inputs such as assumed share prices, volatility, discount factors and other assumptions
and may not be reflective of the price at which they can be settled. Such warrant classification is also subject to re-evaluation at each
reporting period.
Each warrant entitles the holder to
purchase one share of the Company’s common stock at a price of $11.50 per share, subject to adjustment as discussed herein.
In addition, if (x) the Company issues additional shares or equity-linked securities for capital raising purposes in
connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per
share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board
of directors and, in the case of any such issuance to the Company’s Sponsors or its affiliates, without taking into account
any Founder Shares held by the Company’s Sponsors or its affiliates, prior to such issuance) (the “Newly Issued Price”),
(y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon,
available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination
(net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20
trading day period starting on the trading day prior to the day on which the Company consummates the initial Business Combination
(such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to
the nearest cent) to be equal to 115% of the Market Value, and the $18.00 per share redemption trigger price described below under
“Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the Market Value.
The warrants will become exercisable
on the later of 12 months from the closing of this offering or upon completion of its initial Business Combination and will
expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., Eastern Time, or earlier
upon redemption or liquidation.
Redemption of warrants
The Company may call the warrants for
redemption (excluding the private warrants, and any warrants underlying Units issued to the Sponsors, initial stockholders, officers,
directors or their affiliates in payment of related party loans made to the Company), in whole and not in part, at a price of $0.01
per warrant:
● |
at any time while the warrants are exercisable, |
|
|
● |
upon not less than 30 days prior written notice of redemption to each warrant holder, |
|
|
● |
if, and only if, the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the third trading business day prior to the notice of redemption to warrant holders, and |
|
|
● |
if, and only if, there is a current registration statement in effect with respect to the issuance of the shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day until the date of redemption. |
If the Company calls the warrants for
redemption as described above, the management will have the option to require any holder that wishes to exercise its warrant to
do so on a “cashless basis.” If management takes advantage of this option, all holders of warrants would pay the exercise
price by surrendering their warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the
product of the number of shares of common stock underlying the warrants, multiplied by the excess of the “fair market value”
(defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value”
shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior
to the date on which the notice of redemption is sent to the holders of warrants.
If the Company is unable to complete
an initial Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders
of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the
Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.
The following
presents the Company’s fair value hierarchy for the 406,000 Private Warrants issued which are classified as liabilities measured
at fair value as of March 31, 2022:
Schedule of Fair Value Hierarchy |
|
|
|
|
|
|
|
|
Level
1 |
|
Level
2 |
|
Level
3 |
|
|
|
|
|
|
|
Private Warrants |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
101,500 |
|
Total |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
101,500 |
|
The following presents
the Company’s fair value hierarchy for the 406,000 Private Warrants issued which are classified as liabilities measured at
fair value as of the December 31, 2021:
|
|
Level
1 |
|
Level
2 |
|
Level
3 |
|
|
|
|
|
|
|
Private Warrants |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
194,880 |
|
Total |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
194,880 |
|
The following table
summarizes key inputs and the models used in the valuation of the Company’s Private Warrants as of March 31, 2022:
Schedule of private warrants |
|
|
|
|
Valuation Method Utilized |
|
Modified Black Scholes |
Stock Price |
|
$ |
9.89 |
|
Exercise Price |
|
$ |
11.50 |
|
Expected Term |
|
|
5.0 |
|
Volatility |
|
|
4.3 |
% |
Risk-free rate |
|
|
2.42 |
% |
The following table
summarizes key inputs and the models used in the valuation of the Company’s Private Warrants as of December 31, 2021:
Valuation Method Utilized | |
Modified Black
Scholes |
Stock Price | |
$ | 9.81 | |
Exercise Price | |
$ | 11.50 | |
Expected Term | |
| 5.0 | |
Volatility | |
| 9.7 | % |
Risk-free rate | |
| 1.26 | % |
The following table presents the changes
in Level 3 liabilities for the three months ended March 31, 2022:
Schedule of fair value of warrant liability |
|
|
|
|
Fair value of Private Warrants at December 31, 2021 |
|
$ |
194,880 |
|
Change in fair value of Private Warrants |
|
|
(93,380 |
) |
Fair value of Private Warrants at March 31, 2022 |
|
$ |
101,500 |
|
The following table presents the changes
in the Private Warrant liabilities, measured on a recurring basis, classified as Level 3, for the period from January 21, 2021
(inception) to December 31, 2021:
Fair value of Private Warrants at January 21, 2021 (Inception) |
|
$ |
— |
|
Initial fair value of Private Warrants at September 14, 2021 |
|
|
345,100 |
|
Change in fair value |
|
|
(150,220 |
) |
Fair value of Private Warrants at December 31, 2021 |
|
$ |
194,880 |
|
Note 9—Stockholders’
Equity
Preferred
Stock—On September 9, 2021, the Company amended and restated its certificate of incorporation to authorize the issuance
of 1,000,000 shares of preferred stock at par value of $0.01 each and with such designations, voting and other rights and preferences
as may be determined from time to time by the Company’s board of directors.
Common Stock—The
Company was authorized to issue a total of 10,000,000 shares of common stock with par value of $0.01 each. As of March 31, 2022
and December 31, 2021, there were 3,961,500 shares of common stock issued and 2,524,000 shares of common stock outstanding, excluding
6,900,000 shares subject to possible redemption. Each share of common stock entitles the holder to one vote. In connection with
the Company’s amended and restated certificate of incorporation, authorized shares were increased to 100,000,000. As of the
consummation of the Company’s IPO on September 14, 2021, there were 9,424,000 shares of common stock issued, inclusive of
those subject to possible redemption, consisting of (1) 6,900,000 shares related to the Units sold in the IPO, (2) 406,000 shares
related to the Private Placement Units sold concurrently with the IPO, (3) 1,725,000 Founder Shares and (4) 393,000 Representative
Shares.
Treasury
Stock—On June 21, 2021 the Sponsors agreed to deliver the Company 1,437,500 shares of common stock beneficially owned
by the Sponsors. The amount payable to Yezhuvath of $7,735 was repaid as part of the Private Placement Units issued to him (see
Note 5) and the amount of $7,000 payable to Bannix Management LLP is included in Due to Related Parties as of March 31, 2022.
Rights—Except
in cases where the Company is not the surviving company in the Business Combination, each holder of a right will automatically
receive one-tenth (1/10) of a share of common stock upon consummation of the Business Combination, even if the holder of a right
converted all shares held by him, her or it in connection with the Business Combination or an amendment to the Company’s
Certificate of Incorporation with respect to its pre-Business Combination activities. In the event that the Company will not be
the surviving company upon completion of the Business Combination, each holder of a right will be required to affirmatively convert
his, her or its rights in order to receive the one-tenth (1/10) of a share of common stock underlying each right upon consummation
of the Business Combination. No additional consideration will be required to be paid by a holder of rights in order to receive
his, her or its additional share of common stock upon consummation of Business Combination. The shares issuable upon exchange of
the rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enters into a definitive
agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide
for the holders of the rights to receive the same per share consideration the holders of shares of common stock will receive in
the transaction on an as-converted into common stock basis.
Note 10—Subsequent
Events
The Company
evaluated subsequent events and transactions that occurred after the balance sheet date up to the date of the filing of this report.
The Company did not identify any subsequent events, other than those discussed within the notes to these unaudited condensed financial
statements and noted below, that would have required adjustment or disclosure in these unaudited condensed financial statements.
On October
20, 2022, pursuant to a Securities Purchase Agreement, Instant Fame LLC, a Nevada limited liability company, acquired an aggregate
of 385,000 shares of common stock of the Company from Bannix Management LLP, Balaji Venugopal Bhat, Nicholos Hellyer, Subbanarasimhaiah
Arun, Vishant Vora and Suresh Yezhuvath and 90,000 private placement units from Suresh Yezhuvath (collectively, the “Sellers”)
in a private transaction. The Sellers immediately loaned the entire proceeds to the Company for the working capital requirements
of the Company. This loan will be forfeited by the Sellers upon liquidation or business combination. In connection with this transaction,
all parties agreed that there will be certain changes to the Board of Directors.
As a result
of the above, Subash Menon resigned as Chief Executive Officer and Chairman of the Board of Directors of the Company and Nicholas
Hellyer resigned as Chief Financial Officer, Secretary and Head of Strategy. Douglas Davis was appointed as the Chief Executive
Officer of the Company. Further, Balaji Venugopal Bhat, Subbanarasimhaiah Arun and Vishant Vora resigned as Directors of the Company.
Mr. Bhat, Mr. Arun and Mr. Vora served on the Audit Committee with Mr. Bhat serving as the committee chair. Mr. Bhat, Mr. Arun
and Mr. Vora served on the Compensation Committee with Mr. Arun serving as the committee chair.
The Board was
also increased from two to seven and Craig Marshak and Douglas Davis were appointed as Co-Chairmans of the Board of Directors effective
immediately. Further, Jamal Khurshid, Eric T. Shuss and Ned L. Siegel were appointed to the Board of Directors of the Company effective
ten days after the mailing of a Schedule 14f Information Statement. The resignations referenced above were not the result of any
disagreement with management or the Board.